CELL INTELLIGENCE · 肿瘤细胞治疗研究

结合胶原蛋白的 IL-15 免疫细胞因子武装溶瘤腺病毒建立自我强化的免疫刺激环境以增强抗肿瘤免疫

Collagen-Binding IL-15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self-Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immun

放疗增强新型溶瘤疱疹病毒 VG161 的溶瘤效果并放大其在乳腺癌中的抗肿瘤免疫

Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer.

HSVtk 和 IL-15Rα武装的痘苗病毒诱导系统性抗肿瘤免疫的协同溶瘤效应

Synergistic Oncolytic Effect of HSVtk- and IL-15Rα-Armed Vaccinia Viruses Inducing Systemic Antitumor Immunity.

三阴性乳腺癌免疫检查点免疫治疗的进展

Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer.

乳腺癌中的免疫检查点阻断与新兴联合平台：叙述性综述

Immune Checkpoint Blockade and Emerging Combination Platforms in Breast Cancer: A Narrative Review.

乳腺癌免疫治疗：免疫逃逸机制、生物标志物及新兴治疗策略

Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.

减毒新城疫病毒 (NDV) 激活的 NK 细胞作为抗癌治疗

Natural killer cell activated by attenuated newcastle disease virus (NDV) as anti-cancer therapy.

减毒 NDV 显著增强 NK 细胞对乳腺癌细胞的细胞毒性和黏附作用。这种联合策略提供了一种有前景的免疫治疗策略，凸显了将溶瘤病毒治疗与基于 NK 细胞的治疗相结合用于癌症治疗的潜力。

溶瘤病毒 Talimogene laherparepvec 和阿替利珠单抗在新辅助化疗后的 HER2 阴性乳腺癌中的应用：一项机会窗二期试验（SOLTI-1503 PROMETEO）

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (S

三阴性乳腺癌治疗的免疫治疗策略

Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer.

基于 CAR-T/NK/M 的肿瘤联合治疗：全面综述

CAR-T/NK/M-based combination therapies in cancer: A comprehensive review.